Humana announced that it has entered into a definitive agreement with a consortium of investors to divest all or substantially all of its minority interest in Gentiva, the nation’s leading provider of end-of-life services, including hospice and palliative care.
The agreement values Humana’s minority stake in Gentiva at approximately $900 million. Additional financial terms of the transaction were not disclosed. The company said it intends to use the proceeds from the sale for general corporate purposes.
The transaction is expected to close during the third quarter of 2026, subject to customary closing conditions and regulatory approvals. Humana noted that it does not expect the pending transaction to have a material impact on its 2026 earnings.
Humana’s ownership interest in Gentiva originated from its acquisition of the remaining stake in Kindred at Home in 2021. At the time, the company indicated that it intended to eventually divest non-core businesses associated with Kindred at Home, including hospice, palliative care, and personal healthcare services.
In 2022, Humana announced an agreement to sell a majority interest in Kindred at Home’s Hospice and Personal Care divisions to the private investment firm Clayton, Dubilier & Rice. Those businesses were subsequently reorganized into a standalone company and rebranded as Gentiva.
Today, Gentiva is the largest provider of end-of-life care services in the United States, with thousands of clinicians and caregivers serving patients through more than 430 locations across 35 states. The company provides hospice, palliative care, and related support services aimed at improving the quality of life for patients with serious illnesses.
The latest transaction represents another step in Humana’s previously announced strategy of focusing its portfolio on core healthcare and insurance operations. Through its Humana insurance business and CenterWell healthcare services platform, the company provides healthcare solutions to millions of Americans, including Medicare and Medicaid beneficiaries, military personnel, families, and individual consumers.
Guggenheim Securities is serving as financial advisor to Humana on the transaction. Fried, Frank, Harris, Shriver & Jacobson and Manatt, Phelps & Phillips are acting as legal advisors.
The divestiture further simplifies Humana’s business portfolio while allowing the company to redeploy capital into strategic priorities and ongoing operations.
